Innate Pharma S.A. (IPHA)

Innate Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 18, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	168	166	233	282	400	334
Market Cap Growth	14.00%	-29.08%	-17.19%	-29.50%	19.60%	-36.34%
Enterprise Value	129	107	180	196	283	177
Last Close Price	1.76	1.84	2.80	3.73	4.56	4.09
PS Ratio	11.32	7.95	3.43	4.58	14.24	3.92
PB Ratio	27.80	18.11	4.07	4.87	3.27	1.75
P/TBV Ratio	27.80	18.11	4.10	5.02	5.56	2.49
EV/Sales Ratio	8.71	5.15	2.65	3.19	10.07	2.07
EV/EBITDA Ratio	-	-	-	-	-	10.86
EV/EBIT Ratio	-	-	-	-	-	133.87
Debt / Equity Ratio	5.25	3.51	0.77	0.78	0.41	0.12
Debt / EBITDA Ratio	-	-	-	-	-	1.33
Asset Turnover	0.10	0.14	0.33	0.25	0.09	0.20
Quick Ratio	2.08	2.50	3.51	3.21	1.67	3.64
Current Ratio	2.21	2.60	3.73	3.38	1.73	3.81
Return on Equity (ROE)	-271.37%	-162.91%	-14.28%	-71.75%	-34.53%	-0.44%
Return on Assets (ROA)	-25.92%	-22.52%	-4.23%	-4.40%	-10.40%	0.19%
Return on Capital (ROIC)	-65.68%	-48.98%	-8.42%	-8.28%	-18.30%	0.33%
Return on Capital Employed (ROCE)	-79.80%	-66.10%	-9.30%	-10.40%	-25.50%	0.40%
Earnings Yield	-32.20%	-30.93%	-3.58%	-22.02%	-15.02%	-23.41%
FCF Yield	-28.81%	-4.56%	-15.58%	-7.46%	-16.89%	-19.27%
Buyback Yield / Dilution	-4.15%	-0.74%	-1.02%	-0.12%	-0.77%	-17.97%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q